3SOF

Symmetrical Triangle...breakout.
Volume and price action,nice move to the upside.


--------------------------------------------------------------------------------------------------------------------------------

VANCOUVER, British Columbia, Jun 28, 2005 (BUSINESS WIRE) -- MIV Therapeutics, Inc. (MIVT, Trade), a developer of next-generation biocompatible stent coatings and drug delivery technologies, has announced the availability of an extensive research and investment report by SISM Research & Investment Services that projects a 300% increase in share appreciation, and reaffirms a Speculative Buy/4 recommendation of the Company's stock with a 12-month target price of $1.50.

The SISM "Company Insight!" report, authored by leading market analyst Ernest C. Schlotter, concludes that the company's fully biocompatible, ultra-thin HAp coating technology positions it to become a world leader in the coated medical device market.

The report provides a detailed overview of MIVT's proprietary Hydroxyapatite (HAp)-based biocompatible stent coatings and novel drug-delivery solutions designed to address known weaknesses of current drug-eluting systems. The report outlines MIVT's intellectual property portfolio, which was strengthened recently through exclusive licensing of four additional technologies from the University of British Columbia. It also reviews key research milestones achieved to date.

For example, the report states: "In June 2004, MIVT commissioned Toxikon Corp., of Bedford, MA, to complete a full range of twelve biocompatibility studies on its proprietary HAp coating technology. All twelve studies were successful and confirmed HAp's exceptional biocompatibility."

The report adds: "MIVT's HAp stent coating also demonstrated excellent performance and biocompatibility in all key areas at three-month follow-up of porcine trials, paving the way for MIVT to enter the lucrative drug-eluting stent market."

The report also expands on MIVT's key investment and business highlights, including the completed acquisition of SagaX Medical Technologies and an agreement to acquire advanced stent manufacturer Sahajanand Medical Technologies, one of the world's largest manufacturers of advanced coronary stents outside of the U.S. The pending acquisition of Sahajanand is expected to bring MIVT approximately $20 million in revenues in its first year, as well as immediate access to Sahajanand's world-class production facilities and well-established distribution network.

The report concludes: "Based on the Company's strong management team and outstanding proprietary coating technology, MIVT is clearly undervalued, and we reaffirm our Speculative Buy/4 recommendation for the stock of MIV Therapeutics with a 12-month target price of $1.50."

The report is available at http://www.trilogy-capital.com/mivt_summary.aspx.

About MIV Therapeutics

MIV Therapeutics is developing a next generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and other implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction of metal stents. The Company's ultra-thin coating has been derived from a unique biocompatible material called hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and superior healing properties pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug eluting technology provides an alternative solution to polymer-based drug eluting coatings currently in the stent market. A broader spectrum of synthetic parameters allows The Company's drug eluting coating easily and widely applicable to various implantable devices with a pre-designed drug release profile to meet desirable clinical performance. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and supported a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of hydroxyapatite as a drug eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council - Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development program.

For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Copyright (C) 2005 MIV Therapeutics Inc. All rights reserved.

SOURCE: MIV Therapeutics, Inc.


MIV Therapeutics Inc. 
Investors: 
604-301-9545 
Fax: 604-301-9546 
[email protected] 
www.mivtherapeutics.com 
or 
Product Inquiries and Business Opportunities: 
Arc Rajtar, 604-301-9545 Ext. 22 
[email protected] 
or 
Investor Relations: 
Trilogy Capital Partners 
Paul Karon, 800-342-1467 
[email protected] 

Copyright Business Wire 2005

man this one can get cookin, on the watchlist.  Thx setravis - nice pick(applaud)   

VOLUME BUILDING

Breakout.........Ascending Triangle
Record Price High...
Record Price Breakout...
Percentage Gainer...
************************************************************************


VANCOUVER, British Columbia, Jul 08, 2005 (BUSINESS WIRE) -- MIV Therapeutics, Inc. (MIVT, Trade), a developer of next-generation biocompatible stent coatings and drug delivery technologies for the treatment of cardiovascular disease, has reported significant progress in a report outlining the achievement of numerous key corporate and technological objectives for the first half of 2005. MIVT has systematically reinforced its strategic goal to capitalize on proprietary Hydroxyapatite (HAp) coating technologies, which have demonstrated consistently high levels of safety and biocompatibility in repeated scientific studies.

The Company's achievements for the first half of 2005 include execution of a Letter of Intent to acquire India-based Sahajanand Medical Technologies (SMT), the world's third largest manufacturer of drug-eluting stents, and a leading innovator in advanced laser technologies for cost-effective manufacturing of world-class quality cardiovascular stents. During this period, MIVT also successfully acquired SagaX Medical Technologies, a privately held company developing a proprietary Aortic Embolic Protection Device (AEPD), a novel filtration device designed to prevent Cardioembolic Strokes by diverting particles that might otherwise reach the brain. The Sahajanand and SagaX agreements are designed to significantly broaden MIVT's portfolio of technology and expertise, and are expected to provide a major boost to its marketing and commercialization efforts.

"We are very pleased to report that in the first six months of this calendar year were marked with outstanding successes that rewarded our endeavors towards meeting our strategic corporate objectives for 2005," said Alan Lindsay, President and CEO of MIVT. "Our concentrated efforts to develop the core strengths of our proprietary medical device coating technologies are approaching a turning point in MIVT's corporate history. Excellent results from porcine animal trials of the proprietary HAp coating technology and novel drug-eluting solutions confirm their outstanding biocompatibility and safety, and bring a promise of unique therapeutic capabilities. Our recent proposed acquisition of Sahajanand, along with our successfully completed acquisition of SagaX Medical Technologies set a firm foundation for accelerated progress of our technologies to the commercialization stage."

Arc Rajtar, MIVT Vice President of Operations, added: "It has truly been an exceptional year for us thus far. We have received new and exciting validation of our proprietary coating technologies from many sources in and around the biomedical community. These include such events as the successful results from our latest animal trials, and the renewal of government grants and other official endorsements of the HAp-based technologies and products we're developing at an international scale. It is always gratifying to our team to receive independent positive confirmation of MIVT's next-generation coatings, which represent novel and innovative solutions that consistently demonstrate exceptional safety and biocompatibility, and suggest possibilities for significantly improved treatments for heart and cardiovascular disease."

Research & Development Milestones

-- March 2005 -- MIVT completes a successful pilot preclinical studies performed on different formulations of biocompatible Hydroxyapatite (HAp) nano-film coating specifically designed for cardiovascular stents. Independent histopathology studies confirm excellent biocompatibility and safety of the proprietary HAp coating for vascular applications.

-- April 2005 -- MIVT files two new patent applications for inventions developed by the Company's R&D Team, which are expected to enable the development and manufacture of a novel class of advanced composite drug-eluting coatings capable of delivering multiple drugs from a single implantable medical device.

-- April 2005 -- MIVT reports on positive results from several animal studies of the proprietary ultra-thin HAp coating. Consistent and problem-free performance of stents with MIVT's proprietary coatings confirms exceptional safety and biocompatibility of HAp passive coating technologies.

-- April 2005 -- Cardiovascular stents coated with MIVT's proprietary composite drug-eluting coating demonstrate uncompromised and exceptional biocompatibility and safety. The low amount of neointima ranks with the performance of the best contemporary stents described in literature utilizing a similar experimental setting.

-- May 2005 -- MIVT commences preclinical trials of its Aortic Embolic Protection Device (AEPD), a unique proprietary filtration device developed by SagaX Medical Technologies, a company that has been acquired by MIVT. AEPD is designed to divert particles that might otherwise reach the brain and cause strokes.

-- June 2005 -- A three-month follow-up phase of a porcine implantation study of HAp-coated cardiovascular stents demonstrates excellent safety and feasibility of MIVT's HAp-based coating technologies. An interim report on long-term in vivo safety studies performed at the Center for Research in Cardiovascular Interventions at the Methodist Hospital Research Institute in Houston, Texas, confirms earlier predictions of exceptional safety and biocompatibility of the ultra-thin HAp coating technologies at this critical follow-up stage.

Business and Financing Achievements

-- March 2005 -- MIVT executes a Letter of Intent to acquire Sahajanand Medical Technologies (SMT), one of the world's largest manufacturers of advanced coronary stents. Based in Surat, India, SMT is a leader in the use of high-precision laser technology, and a leading manufacturer of state-of-the-art drug-eluting and non-drug-eluting stents. Established in 1997, SMT is the largest privately-held producer of coronary drug-eluting stents outside of North America, with its stent products sold in more than 33 countries and used in more than 30,000 implants. The Company expects to cross the benchmark of 50,000 implanted stents this year.

-- March 2005 -- MIVT acquires SagaX Medical Technologies, a privately held company developing a unique Aortic Embolic Protection Device (AEPD). The AEPD is expected to decrease likelihood of strokes and other frequent, serious complications that can result from cardiac procedures, as well as from naturally occurring Cardioembolic Strokes. The market for AEPD is estimated to exceed $1.5 billion by 2009.

-- March 2005 -- MIVT receives governmental Natural Sciences and Engineering Research Council of Canada (NSERC) grant for research program entitled, "Development of Novel Drug-Eluting Composite Coatings for Cardiovascular Stents." The research is being conducted by MIVT subsidiary MIVI Technologies, Inc. in cooperation with scientists from the University of British Columbia.

-- June 2005 -- MIVT exercises the option provided in its Collaborative Research Agreement with the University of British Columbia to license four additional technologies for advanced biocompatible and drug-eluting coatings for cardiovascular stents and other medical devices to further the Company's research and development program.

Industry Recognitions and Scientific Presentations

-- April 2005 -- Dr. Dov Shimon, Chief Medical Officer and Director of MIV Therapeutics Inc. presents MIVT's business and growth strategy based on the Company's unique HAp-based multi-layer/multi-drug delivery systems for vascular stents at the Third Annual Biotechnology Conference in New York, N.Y.

-- April 2005 -- MIVT announces the online availability (http://www.trilogy-capital.com/tcp/mivt/video.html) of a video presentation of the Company's advanced biocompatible and drug-eluting coatings for cardiovascular stents and other medical devices. The unique passive biocompatible features combined with the active drug-elution functionality of the HAp coating are expected to reduce inflammation and eliminate some complications that are often attributable with currently available cardiovascular stents and other implanted medical devices.

-- May 2005 -- Dr. Tom Troczynski, PhD, Vice President of Coatings of MIV Therapeutics Inc., and a Professor of Ceramics at UBCeram in the Materials Engineering Dept. of the University of British Columbia, delivers a public presentation entitled, "Progress in Development of Composite Calcium Phosphate Coatings for Stents," and other MIVT Advanced Coating Technologies at the 4th European Symposium of Vascular Biomaterials in Strasbourg, France.

-- May 2005 -- BiomedDiscoveries.com, an online source for exclusive investor information, announces the availability of an audio interview featuring CEO Alan Lindsay, who discusses the benefits of MIVT's recent acquisition of SagaX Medical Technologies.

-- May 2005 -- MIV Therapeutics makes debut at the Paris Course on Revascularization (PCR2005) in Paris, France, sharing an exposition booth with potential future partner, Sahajanand Medical Technologies, Pvt. Ltd.

-- June 2005 -- MIVT is featured in a recent edition of respected European medical industry publication, Cardiovascular News.

Strengthened Management

-- May 2005 -- Mr. Dhirajlal Kotadia, founder and CEO of India-based advanced stent manufacturer, Sahajanand Medical Technologies, is appointed to the position of Co-Chairman and Managing Director of International Operations for MIVT. Mr. Kotadia pioneered the use of advanced laser cutting technology that transformed the jewelry diamond-cutting industry, founded Sahajanand Medical Technologies in 1998 and has since built the company into the third-largest maker of drug-eluting stents in the world.

About MIV Therapeutics, Inc.

MIV Therapeutics Inc. is developing a next generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and other implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company's unique ultra-thin coating has been derived from a biocompatible material called hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and superior healing properties pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug eluting technology provides an alternative solution to polymer-based drug eluting coatings currently in the stent market. The Company's drug eluting coating is designed to suit a broad range of implantable medical devices which may benefit from a highly customizable drug release profile. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and supported a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council -- Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Copyright (C) 2005 MIV Therapeutics Inc. All rights reserved.

SOURCE: MIV Therapeutics, Inc.


MIV Therapeutics Inc. 
Investors: 
Phone: 604-301-9545 
Fax: 604-301-9546 
E-mail: [email protected] 
Web: www.mivtherapeutics.com 
or 
for Product Inquiries and Business Opportunities: 
Arc Rajtar, 604-301-9545 Ext. 22 
[email protected] 
or 
Trilogy Capital Partners 
Paul Karon, 800-342-1467 
[email protected] 

Copyright Business Wire 2005

Good pick, applaud setravis. May start half position on Monday

Zoom..Zoom...Zoom...
Nice move with some volume.

holey moley moley!  this ones on fire..on the path to $1  nice pick setravis(applaud!)

Quote from: eliteG on July 11, 2005, 11:20:57 AM
holey moley moley! this ones on fire..on the path to $1 nice pick setravis(applaud!)

Thanks G ,For the kind words my friend!! I hope you just put your Wizard spell on by the sole mention of $1.

Looking good.
Nice volume and price action on this penny today.

Looking good................

****************************

MIV THERAPEUTICS INC (OTC BB:MIVT.OB) Delayed quote data 

Last Trade: 0.95
Trade Time: 3:42PM ET
Change:  0.09 (9.83%)
Prev Close: 0.87
Open: 0.88
Bid: 0.93 x 2500
Ask: 0.95 x 2500
1y Target Est: N/A

  Day's Range: 0.87 - 0.96
52wk Range: 0.16 - 0.89
Volume: 824,664
Avg Vol (3m): 348,683
Market Cap: N/A
P/E (ttm): N/A
EPS (ttm): N/A
Div Yield (ttm): N/A (N/A)

Looking good. Break of the $1.00 level
Support @ 0.94
MACD and Stochastic are Bullish.


MIV Therapeutics, Inc. (OTCBB:MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies for cardiovascular stents and for a broad range of implantable medical devices, announced Monday that the company had received a $4.14 million equity financing to accelerate research efforts.

Looking good this morning.


Volume now @ 668,419.........+17.92%

Press Release Source: MIV Therapeutics Inc.


MIVT Receives Prestigious Frost & Sullivan 2005 Award for Technology Innovation in Field of Medical Coatings
Wednesday August 24, 4:01 pm ET 
Biocompatible Coating Pioneer Recognized for Development of Visionary Hydroxyapatite (HAp) Coating Technologies


VANCOUVER, British Columbia--(BUSINESS WIRE)--Aug. 24, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation biocompatible passive and drug-eluting stent coatings and drug delivery technologies for the treatment of cardiovascular disease, has been recognized by Frost & Sullivan with the 2005 Technology Innovation Award, in recognition of the Company's achievements and pioneering work to develop proprietary biocompatible coatings technology to make better, safer vascular stents, medical devices and drug delivery systems.



Frost & Sullivan, a widely respected global independent research and growth consulting firm, presents the annual Technology Innovation Award to recognize the quality and depth of a company's research and development program, as well as the vision that enabled it to undertake such an endeavor. Frost & Sullivan's Technology Innovation Award is bestowed upon a company or individual that has carried out new research that has resulted in innovation(s) that have or are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. The selection process includes primary participant interviews and extensive primary and secondary research.

"MIV Therapeutics has utilized an entirely new approach for medical coatings vis-a-vis the classic polymer-plus-drug coatings," the Frost & Sullivan award announcement notes. "MIVT's Hydroxyapatite (HAp) coatings are entirely biocompatible and promote tissue healing while demonstrating the optimal growth of endothelium. It is in acknowledgement of the company's development of such breakthrough advanced biocompatible medical coatings for stents and other medical devices that it has been recognized with Frost & Sullivan's prestigious Award for Technology Innovation."

Frost & Sullivan's 115-page comprehensive research service entitled, "Advances in Coatings Technology for Medical Devices and Drug Delivery" contains an extensive analysis of MIVT's technology and development initiatives.

Frost & Sullivan's Technical Insights Group discussed the development of MIV Therapeutics' pioneering, completely biocompatible Hydroxyapatite (HAp) technology for medical coatings, and its potential to improve stents and other implantable devices, as well as advanced drug delivery systems. The research service reviews current medical device coatings technologies, innovations, and market trends. The research service on MIVT can be purchased through the Frost & Sullivan website at http://www.frost.com.

MIV Therapeutics is developing and pursuing the commercialization of safe and fully biocompatible coatings for stents and other medical devices with the intent of providing improved solutions for the treatment of cardiovascular disease and other conditions. In collaboration with the University of British Columbia, MIVT is focused on developing a proprietary ultra-thin coating formulation to protect surrounding tissue from chemical interaction with bare-metal stents, an interaction which typically causes aggressive response of the immune system resulting in elevated restenosis, or renarrowing of arteries, and a risk of thrombus in the stented artery. MIVT's innovative coatings are based upon a natural material, Hydroxyapatite, a component of hard tissue found in certain parts of the human body, such as bone, which enables the surface of metallic stents to virtually mimic the natural state of structurally-sound 100% biocompatible and bio-active tissue.

"The Frost & Sullivan Technology Innovation Award is the latest validation of our innovative development of our next-generation Hydroxyapatite coatings for stents and other implantable medical devices," said Alan Lindsay, CEO of MIVT. "It's particularly rewarding that an organization of Frost & Sullivan's caliber and reputation singled out MIVT as a leader in the large and important medical coatings sector. This award provides yet another indication of the potential of our advanced coating solutions to provide significant impact on multimillion-dollar biomedical market sectors. We are certainly proud of this recognition and believe that our technology will continue to set benchmarks for the next-generation bio-friendly coatings in numerous cardiovascular and other medical device segments worldwide."

Unlike stent and drug-eluting coatings currently in use, MIVT's HAp coatings are designed to inhibit adverse reactions of the body immune system. Exceptional biocompatibility and safety of HAp coatings are believed to be the key attributes that may potentially help to reduce restenosis, or re-blocking of the arteries following angioplasty. In particular, MIVT's coatings are designed to reduce risks of thrombogenic (blood clotting) events attributable in some instances to polymer-coated stents. MIVT has successfully completed a comprehensive range of biocompatibility and histopathology tests on its product and recently completed, with very encouraging results, a 3-month phase of porcine animal trials that confirmed exceptional safety and biocompatibility of HAp coatings in coronary arteries. Human clinical trials are expected to commence soon. MIVT believes its technology also has potential for an array of additional medical applications, including dental, hip and bone repair implants.

About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.

About MIV Therapeutics, Inc.

MIV Therapeutics Inc. is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and for application on other implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company's unique ultra-thin coating has been derived from a biocompatible material called hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and superior healing properties pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug eluting technologies based on Hydroxyapatite provide attractive alternative solution to polymer-based drug eluting coatings currently in the stent market. The Company's drug eluting coating is designed to suit a broad range of implantable medical devices which may benefit from a highly customizable drug release profile. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and supported a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council -- Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.



--------------------------------------------------------------------------------
Contact:
     MIV Therapeutics Inc.
     Investor Relations, 604-301-9545
     Toll-free: 800-221-5108
     Fax: 604-301-9546
     E-mail: [email protected]
     Web: www.mivtherapeutics.com
     Or for Product Inquiries and Business Opportunities:
     Arc Rajtar, 604-301-9545 Ext. 22
     [email protected]
     or
     Trilogy Capital Partners
     Paul Karon, Toll-free: 800-342-1467
     [email protected]



--------------------------------------------------------------------------------
Source: MIV Therapeutics Inc.

Press Release Source: Beacon Research Partners


MIV Technologies Research Note Issued by Investrend Research Affiliate Beacon Equity Research Regarding New Financing and Award
Thursday August 25, 8:30 am ET


NEW YORK--(BUSINESS WIRE)--Aug. 25, 2005--(Investrend Research Syndicate) A research note on MIV Technologies, Inc. (OTCBB: MIVT - News) has been issued by Investrend Research Affiliate Beacon Equity Research analyst Shailesh Dhuri, CFA.



The full report is available at http://www.beaconequityresearch.com and http://www.investrendresearch.com

In the report Mr. Dhuri writes, "In 2004, the Company successfully completed biocompatibility tests that have proven the exceptional capabilities of HAp as a coating for medical devices and delivery technologies. Preliminary safety studies were also successfully completed and it is confirmed, according to the Company, that HAp is suitable for the use of cardiovascular applications. The final stage of commercializing HAp is Human clinical trials and this stage is expected to commence in near future.

The Company has recently announced that it has been recognized by Frost & Sullivan with the "2005 Technology Innovation Award", in recognition of the Company's achievements and pioneering work to develop proprietary biocompatible coatings technology to make better, safer vascular stents, medical devices and drug delivery systems. This type of recognition should help MIV in many ways, such as attracting capital; attracting potential partners for sharing the risks of developments; and helping prepare the market for easy acceptance when the product is eventually launched.

Regarding the financing, in our valuation model, we had explicitly estimated there would be high costs involved with the process of getting a new coating approved by the FDA. It is vitally important that they are able to attract new capital on favorable terms (such as the current placement) to cover new research expenses and satisfy its burn-rate. The deal implies that larger investors who have decided to fund the recent round development have found it economically appealing to invest funds in this venture, at the current level of valuation."

Beacon Equity Research, LLC is a fee-based, comprehensive investment research firm, focusing primarily on the underserved small-cap sector. All Beacon analysts are seasoned industry professionals and adhere to the CFA Institute's (CFAI) stringent ethics and standards of practice guidelines. Beacon Research does not have any investment banking relationships with any of the companies covered. All analysts are compensated prior to performing their investment research and are not compensated in any way based on the future performance of the equities they follow.

Both Beacon Equity Research and Investrend subscribe to the "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com. Beacon Research Partners has been compensated $18,000 by MIV Therapeutics, Inc. for a one year enrollment in its research program.

Complete information is available at the company's InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes. Investors are advised to read disclosures carefully before trading in the equities of any enrolled company.

Anyone interested in receiving alerts regarding MIV Therapeutics research should email [email protected] with "MIVT" in the subject line.



--------------------------------------------------------------------------------
Contact:
     Beacon Equity Research
     Jeff Bishop, 972-200-5519
     [email protected]
     www.beaconequityresearch.com
     or
     Investrend Research
     R. Hempel, 718-896-5060
     [email protected]
     www.investrendresearch.com



--------------------------------------------------------------------------------
Source: Beacon Research Partners

Wow setravis, awesome picks!